Safe use of antirheumatic agents in patients with comorbidities.

Rheum Dis Clin North Am

Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.

Published: November 2012

The burden of comorbid diseases is high among patients with rheumatoid arthritis (RA). These are often systemic manifestations of RA but may be chronic conditions that predate or develop post-RA diagnosis. Increased mortality in RA is predominantly from nonarticular causes. The expanded armamentarium of disease-modifying drugs and biologics available has revolutionized management of articular disease but has made safe treatment of RA more complex. Drug-induced organ injury and side effects need to be kept in mind when initiating or modifying therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rdc.2012.08.013DOI Listing

Publication Analysis

Top Keywords

safe antirheumatic
4
antirheumatic agents
4
agents patients
4
patients comorbidities
4
comorbidities burden
4
burden comorbid
4
comorbid diseases
4
diseases high
4
high patients
4
patients rheumatoid
4

Similar Publications

Acute liver failure (ALF) is characterized by rapid hepatic dysfunction, primarily caused by drug-induced hepatotoxicity. Due to the lack of satisfactory treatment options, ALF remains a fatal clinical disease, representing a grand challenge in global health. For the drug repositioning to ALF of mesalamine, which is clinically approved for the treatment of inflammatory bowel disease (IBD), we propose a supramolecular prodrug nanoassembly (SPNs).

View Article and Find Full Text PDF

Objective: This paper aims to review the efficacy and safety of current chronic urticaria (CU) treatment in children and the existing patient-reported outcome measures (PROMs) used in this age group.

Data Source: Since there are few studies of CU in children, the authors performed a non-systematic review of published articles in English, Spanish, and Portuguese in the PubMed database in the last decade. Keywords used were (antihistamines OR omalizumab OR cyclosporine OR treatment) AND (chronic urticaria) AND (children OR adolescents).

View Article and Find Full Text PDF

Methotrexate-associated lymphoproliferative disorder (MTX-LPD) constitutes a subset of lymphoid proliferations and lymphomas that are associated with immune deficiency and dysregulation. The clinical management of MTX-LPDs is contingent on their histopathological subtypes. Polatuzumab vedotin is a novel therapeutic approach that is particularly beneficial for selecting patients with previously untreated diffuse large B-cell lymphoma (DLBCL); however, DLBCL-type MTX-LPD is still treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) because of the exclusion of MTX-LPD from clinical trials.

View Article and Find Full Text PDF

Cancers still globally endanger millions of people yearly; the incidences/mortalities of colorectal cancers are particularly increasing. The natural nanoparticles (NPs) and marine biopolymers were anticipated to provide effectual safe significances for managing cancers. The transformation of curcumin to nano-curcumin (NCur) was conducted with gum Arabic.

View Article and Find Full Text PDF

Objective: To analyze the efficacy and tolerability of aceclofenac in the treatment of patients with acute non-specific musculoskeletal pain in the lower back (ANBP) compared with other NSAIDs (dexketoprofen, nimesulide and lornoxicam), as well as to assess the impact of NSAIDs therapy on the relative risk of recurrence and chronicity of this pathology.

Material And Methods: The study involved 80 patients (47 women and 33 men), average age 52.6 [47.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!